Evidence map›Paper›PMID 29723273›Full record

ArticlePloS one2018

Distinct roles for REV-ERBα and REV-ERBβ in oxidative capacity and mitochondrial biogenesis in skeletal muscle.

Ariadna Amador, Sean Campbell, Melissa Kazantzis, Gary Lan, Thomas P Burris, Laura A Solt

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ariadna AmadorKellogg School of Science and Technology, The Scripps Research Institute, Jupiter, Florida, United States of America.
Sean CampbellDepartment of Immunology and Microbiology, The Scripps Research Institute, Jupiter, Florida, United States of America.
Melissa KazantzisMetabolic Core, The Scripps Research Institute, Jupiter, Florida, United States of America.
Gary LanDepartment of Immunology and Microbiology, The Scripps Research Institute, Jupiter, Florida, United States of America.
Thomas P BurrisDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, Missouri, United States of America.
Laura A SoltDepartment of Immunology and Microbiology, The Scripps Research Institute, Jupiter, Florida, United States of America.ORCID 0000-0001-8807-0342
Scripps Research Institute · USSaint Louis University · US

Funding

REV-ERB ligands for treatment of anxiety disordersR01MH093429 · NIMH · SCRIPPS FLORIDA · PI BURRIS, THOMAS P · 2012 to 2016
$3.6M
Regulation of TH17 Cell Development and Function by the REV-ERBsR01AI116885 · NIAID · SCRIPPS FLORIDA · PI SOLT, LAURA A · 2016 to 2020
$2.1M
Regulation of TH17 cell development and function by the REV-ERBsR56AI116885 · NIAID · SCRIPPS FLORIDA · PI SOLT, LAURA A · 2015 to 2015
$480k
NIAID NIH HHS R01 AI116885NIAID NIH HHS R56 AI116885NIH HHS R01AI116885NIH HHS R01MH093429NIMH NIH HHS R01 MH093429
6 · The paper itself

Abstract

The nuclear receptors REV-ERBα and REV-ERBβ have been demonstrated to be core members of the circadian clock and participate in the regulation of a diverse set of metabolic functions. Due to their overlapping tissue expression patterns and gene expression profiles, REV-ERBβ is thought to be redundant to REV-ERBα. Recent work has highlighted REV-ERBα's role in the regulation of skeletal muscle oxidative capacity and mitochondrial biogenesis. Considering the similarity between the REV-ERBs and the hypothesized overlap in function, we sought to determine whether REV-ERBβ-deficiency presented with a similar skeletal muscle phenotype as REV-ERBα-deficiency. Ectopic overexpression in C2C12 cells demonstrated that REV-ERBβ drives mitochondrial biogenesis and the expression of genes involved in fatty acid oxidation. Intriguingly, knock down of REV-ERBβ in C2C12 cultures also resulted in mitochondrial biogenesis and increased expression of genes involved in fatty acid β-oxidation. To determine whether these effects occurred in vivo, we examined REV-ERBβ-deficient mice and observed a similar increase in expression of genes involved in mitochondrial biogenesis and fatty acid β-oxidation. Consistent with these results, REV-ERBβ-deficient mice exhibited an altered metabolic phenotype compared to wild-type littermate controls when measured by indirect calorimetry. This likely compensated for the increased food consumption that occurred, possibly aiding in the maintenance of their weight over time. Since feeding behaviors are a direct circadian output, this study suggests that REV-ERBβ may have more subtle effects on circadian behaviors than originally identified. Furthermore, these data implicate REV-ERBβ in the control of skeletal muscle metabolism and energy expenditure and suggest that development of REV-ERBα versus REV-ERBβ selective ligands may have therapeutic utility in the treatment of metabolic syndrome.

Indexed as

AnimalsBody WeightCalorimetry, IndirectCell LineCircadian RhythmEnergy MetabolismFatty AcidsFeeding BehaviorFemaleGene Expression RegulationMaleMiceMice, KnockoutMitochondria, MuscleMuscle, SkeletalNuclear Receptor Subfamily 1, Group D, Member 1Fatty AcidsNr1d1 protein, mouseNr1d2 protein, mouseNuclear Receptor Subfamily 1, Group D, Member 1Receptors, Cytoplasmic and NuclearRepressor ProteinsRNA, Small Interfering

Identifiers

PMID29723273
PMCPMC5933789
OpenAlexW2801512104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.